AbbVie Dividend and Recent News: Key Insights Before Jul 15, 2025

AbbVie Inc. (ABBV) recently announced a dividend of $1.640 per share, set for an ex-dividend date of Jul 15, 2025. This dividend surpasses the average of the last ten dividends, which stood at $0.979 per share. The announcement was made on Jun 20, 2025, with the payment scheduled for Aug 15, 2025. The last dividend was also $1.640 per share, distributed on May 15, 2025. Both dividends are categorized as cash distributions.

In recent developments, AbbVie has made significant strides in the biopharmaceutical industry. As of late, the company has gained a competitive edge over Bristol Myers, driven by robust growth in its Skyrizi and Rinvoq products. This growth has effectively countered the declines in Humira sales and addressed portfolio challenges, according to industry analysts.

Additionally, AbbVie's recent collaboration with Ichnos Glenmark Innovation highlights its strategic focus on advancing oncology treatments. The partnership is set to expedite the development of ISB 2001, showcasing AbbVie's commitment to innovative cancer therapies. This move aligns with the company's broader strategy to enhance its BEAT®-enabled assets in the oncology space.

Over the past week, AbbVie has also experienced a notable boost in its stock performance, with shares surging 3.61% in relation to advancements in its cancer therapy offerings. This increase marks a three-day winning streak, culminating in a cumulative gain of 3.93%. Such positive market movements reflect investor confidence in AbbVie's strategic direction and operational health.

In conclusion, AbbVie's recent dividend announcement and strategic advancements underscore its solid positioning in the pharmaceutical sector. Investors should note that Jul 15, 2025, is the last opportunity to purchase AbbVie stocks and be eligible for the upcoming dividend. Any purchases made post this ex-dividend date will not qualify for the dividend payout.